PharmaTher Granted FDA Orphan Drug Designation for Ketamine to Treat Status Epilepticus
PharmaTher (PHRM) is developing a treatment for a rare, seizure-inducing disorder called Status Epilepticus using ketamine. This week, it was granted a designation that will save them millions of dollars in the process.
It’s called an Orphan Drug Designation and it gives the company potential tax credits, grant eligibility, and marketing exclusivity, and waives a $2.4M New Drug Application fee. It’s designed to incentivize R&D of treatments for rare conditions.
PharmaTher previously received the designation for ketamine to treat ALS and complex regional pain syndrome too!
